drugset / Trial / NCT06394713

A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

NCT06394713

Phase 1/2 Not yet recruiting 60 enrolled Qilu Pharmaceutical Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.

Timeline

Start
2024-06-15
Primary completion
2025-06-15
Completion
2026-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject Irinotecan Small molecule 125 mg/m2 Intravenous
Subject QLF31907 Unknown Intravenous

Indications